ASH 2013: Dr Jeff Sharman Discusses the Ideal Design of Phase 3 Trials with Novel Agent versus the Reality in the Community

Hi friends,

I just posted on my blog bkoffman.blogspot.com an interesting interview with the very lucid Dr. Sharman on the trials of clinical trial design.

This is important for anyone who is considerign enterign a clinical trial

Let me know what you think

Thanks

Brian

2 Replies

oldestnewest
  • Thanks for this Brian, my initial reaction was that it seemed unfair that the better option was not being offered to 50 per cent of those on the trial. I was molified somewhat at the crossover option, but still wonder whether there is a yet unmentioned drug that has passed initial trials that could be used in such a trial.

    Guess phase 3 is more of a proving trial.. If so perhaps we can look forward to a reasonably early release.

    Bubnjay

  • Should be approved this year in the USA if all goes well

You may also like...